Bio-Synthesis provides comprehensive custom antibody packages and immunological services, including epitope prediction, custom antibody synthesis
,carrier protein conjugation, immunization and purification, ELISA analysis, antibody labeling, and antibody microarrays. BSI offers peptide antigen design, using a proprietary Antigen Identifier TM design tool. Anti-peptide polyclonal antibody production is performed with the best titer guarantee in the industry, by implementing a proprietary SP-MaxTM adjuvant, a new family of adjuvants with improved properties, but minimal toxicity. BSI works with host animals under USDA license and holds an NIH Animal Welfare Assurance from the Office of Laboratory Animal Welfare for immunization. All procedures performed during immunization are described in our Standard Operation Procedures (SOPs) to ensure a high-quality product.
All custom polyclonal antibody projects are treated with strict confidentiality. Used animals, developed antigens remain the exclusive property of the customer.
From antigen selection to antibody purfication, BSI has optimized each step of the antibody production process to provided the best antibodies available.
We offer 8 standard custom antibody protocols (combinations of hosts and protocol timeframe) and 6 standard antibody packages (combinations of provisions, antigen and deliverables). For information about a particular protocol, see our Polyclonal Antibody Services below or request a quote today.
- Single anti-peptide polyclonal antibody
- Peptide phospho-specific polyclonal antibody
- Multiple-peptide co-immunization
- Multiple antigen peptide (MAP) polyclonal antibody
- User-supplied antigen
- Create-your-own antibody packages
Why choose Bio-Synthesis for your custom polyclonal antibody services?
Advanced antigen design- Proprietary Antigen Identifier design tool with team of expert scientist to assist client for best peptide antigen selection
- Supreme adjuvant SP-MAX technology
- A new family of adjuvants with improved properties, but minimal toxicity which ensures high specificity and titer of the produced antibodies.
- ELISA Guarantee
- Our polyclonal antibodies have an ELISA titer of 1:20,000 or better for any host if peptide antigens were designed, synthesized, and conjugated by Bio-Synthesis.
Comprehensive antibody packages
- Single anti-peptide polyclonal antibody
- Peptide phospho-specific polyclonal antibody
- Multiple-peptide co-immunization
- Multiple antigen peptide (MAP) polyclonal antibody
- User-supplied antigen
- Create-your-own antibody packages
Custom BNA Synthesis
Custom BNA (Bridged Acid Synthesis), was first described by Wengel and co-workers in 1998 as a novel class of conformationally restricted oligonucleotide analogues. LNA is a bicyclic nucleic acid where a ribonucleoside is linked between the 2'-oxygen and the 4'-carbon atoms via a methylene unit was the earlier generation of cyclic nucleic acid.
Bridged nucleic acid 2',4'-BNANC
(2'-O,4'-aminoethylene bridged nucleic
acid) is a compound containing a six-member bridged
structure with an N-O linkage.
This novel nucleic acid analogue can be synthesized and incorporated
into oligonucleotides. When compared to the earlier generation of LNA,
BNA was found to possess:
- Higher binding affinity against an RNA complement
- Excellent single-mismatch discriminating power
- Enhanced RNA selective binding
- Stronger and more sequence selective triplex-forming characters
- Stronger nuclease resistance to endo and exo-nucleases, even higher than the S(p)-phosphorothioate
analogue.
Oligonucleotides containing BNA exhibit unprecedented thermal stability towards complementary DNA and RNA2, which allows excellent mismatch discrimination. In fact, the high binding affinity of BNA oligos is recommended for use in any hybridization assay that requires high specificity and/or reproducibility such as
- Labeled probes
- In situ hybridization probe
- SNP genotyping
- DNA MicroArray expression analysis
- Allele Specific
- mRNA sample preparation
- Molecular Beacons and PCR primers
As a result of these significant characteristics, the use of BNA-modified oligos in antisense drug development is now coming under investigation4 and, recently, the therapeutic potential of BNA has been reviewed.5 BSI offers BNA Synthesis with great flexibility. For more information on custom BNA synthesis, call 800-227-0627 or write to us at biosyn@biosyn.com
- Deprotected, desalted and ready to use
- Multi-scale capacities
- Purification by PAGE or RP-HPLC upon request
- QC analysis by MALDI-TOF Mass spectrometry, HPLC, PAGE analysis
- Fast delivery with high throughput capacity
References:
(1a) A.A. Koshkin, S.K. Singh, P. Nielsen, V.K. Rajwanshi, R. Kumar, M. Meldgaard, C.E. Olsen, and J. Wengel, Tetrahedron,1998, 54, 3607-3630.
(1b) S.K. Singh, P. Nielsen, A.A. Koshkin, and J. Wengel, Chem. Comm., 1998, (4), 455-456.
(2) L. Kværnø and J. Wengel, Chem. Comm., 1999, (7), 657-658.
(3) P. Mouritzen, A.T. Nielsen, H.M. Pfundheller, Y. Choleva, L. Kongsbak, and S. Møller, Expert Review of Molecular Diagnostics, 2003, 3(1), 27-38.
(4a) J. Kurreck, E. Wyszko, C. Gillen, and V.A. Erdmann, Nucleic Acids Res., 2002, 30, 1911-1918.
(4b)H. Ørum and J. Wengel, Curr. Opinion in Mol. Therap., 2001, 3, 239-243.
(5a) M. Petersen and J. Wengel, Trends in Biotechnology, 2003, 21(2), 74-81.
(5b) D.A. Braasch, D.R. Corey, Biochemistry, 2002, 41, 4503-4510.
